These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

468 related articles for article (PubMed ID: 17200777)

  • 1. Inhibition of clot formation process by treatment with the low-molecular-weight heparin nadroparin in patients with carotid artery disease undergoing angioplasty and stenting. A thromboelastography study on whole blood.
    Konstantinidis K; Gerasimidis T; Verdy E; Elalamy I; Samama MM; Gerotziafas GT
    Thromb Haemost; 2007 Jan; 97(1):109-18. PubMed ID: 17200777
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Aging and venous thromboembolism influence the pharmacodynamics of the anti-factor Xa and anti-thrombin activities of a low molecular weight heparin (nadroparin).
    Mismetti P; Laporte-Simitsidis S; Navarro C; Sié P; d'Azemar P; Necciari J; Duret JP; Gaud C; Decousus H; Boneu B
    Thromb Haemost; 1998 Jun; 79(6):1162-5. PubMed ID: 9657442
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In vitro anticoagulation monitoring of low-molecular-weight heparin.
    Wang JQ; Shi XB; Yang JG; Hu DY
    Chin Med J (Engl); 2009 May; 122(10):1199-202. PubMed ID: 19493471
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of nadroparin, enoxaparin, and unfractionated heparin on endogenous factor Xa and IIa formation and on thrombelastometry profiles.
    Cvirn G; Wagner T; Juergens G; Koestenberger M
    Blood Coagul Fibrinolysis; 2009 Jan; 20(1):71-7. PubMed ID: 20339323
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of nadroparin, enoxaparin, and unfractionated heparin on endogenous formation of factor Xa and IIa and on thrombelastometry profiles in cord versus adult blood.
    Cvirn G; Hoerl G; Tafeit E; Heinl N; Wodrig K; Wagner T; Koestenberger M; Juergens G
    Neonatology; 2011; 100(1):23-31. PubMed ID: 21150227
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Additive effect of the combined administration of low molecular weight heparin and recombinant hirudin on thrombus growth in a rabbit jugular vein thrombosis model.
    Biemond BJ; Levi M; Nurmohamed MT; Büller HR; ten Cate JW
    Thromb Haemost; 1994 Sep; 72(3):377-80. PubMed ID: 7855787
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dalteparin dose-dependently increases ROTEM(®) thrombelastography parameters only at supratherapeutic anti-factor Xa levels: an in vitro study.
    Feuring M; Wehling M; Schultz A
    Clin Exp Pharmacol Physiol; 2011 Nov; 38(11):783-6. PubMed ID: 21883380
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The correlation between plasma anti-factor Xa activity and haemostatic tests in healthy dogs, following the administration of a low molecular weight heparin.
    Mischke R; Grebe S
    Res Vet Sci; 2000 Dec; 69(3):241-7. PubMed ID: 11124095
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacodynamics and tolerance of two nadroparin formulations (10,250 and 20,500 anti Xa IU x ml(-1)) delivered for 10 days at therapeutic dose.
    Boneu B; Navarro C; Cambus JP; Caplain H; d'Azemar P; Necciari J; Duret JP; Gaud C; Sié P
    Thromb Haemost; 1998 Feb; 79(2):338-41. PubMed ID: 9493587
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Anticoagulative effects of the inhaled low molecular weight heparin certoparin in healthy subjects.
    Scheuch G; Brand P; Meyer T; Herpich C; Müllinger B; Brom J; Weidinger G; Kohlhäufl M; Häussinger K; Spannagl M; Schramm W; Siekmeier R
    J Physiol Pharmacol; 2007 Nov; 58 Suppl 5(Pt 2):603-14. PubMed ID: 18204174
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Investigation of the effect of kaolin and tissue-factor-activated citrated whole blood, on clot-forming variables, as evaluated by thromboelastography.
    Johansson PI; Bochsen L; Andersen S; Viuff D
    Transfusion; 2008 Nov; 48(11):2377-83. PubMed ID: 18657078
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of the pharmacokinetic profiles of three low molecular mass heparins--dalteparin, enoxaparin and nadroparin--administered subcutaneously in healthy volunteers (doses for prevention of thromboembolism).
    Collignon F; Frydman A; Caplain H; Ozoux ML; Le Roux Y; Bouthier J; Thébault JJ
    Thromb Haemost; 1995 Apr; 73(4):630-40. PubMed ID: 7495071
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Suppression of intimal hyperplasia with low molecular weight heparin in a sheep model.
    Ao PY; Hawthorne WJ; Coombs R; Fletcher JP
    Int Angiol; 1999 Jun; 18(2):131-9. PubMed ID: 10424369
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Potent arterial antithrombotic effect of direct factor-Xa inhibition with ZK-807834 administered to coronary artery disease patients.
    Zafar MU; Farkouh ME; Osende J; Shimbo D; Palencia S; Crook J; Leadley R; Fuster V; Chesebro JH
    Thromb Haemost; 2007 Mar; 97(3):487-92. PubMed ID: 17334518
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Monitoring high-dose heparinization during cardiopulmonary by-pass--a comparison between prothrombinase-induced clotting time (PiCT) and two chromogenic anti-factor Xa activity assays.
    Raivio P; Kuitunen A; Petäjä J; Ilveskero S; Lassila R
    Thromb Haemost; 2008 Feb; 99(2):427-34. PubMed ID: 18278195
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Xa inhibition and coagulation activity--the influence of prolonged dalteparin treatment and gender in patients with acute coronary syndrome and healthy individuals.
    Oldgren J; Johnston N; Siegbahn A
    Am Heart J; 2008 Mar; 155(3):493.e1-8. PubMed ID: 18294482
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacodynamics of low molecular weight heparin in patients undergoing bariatric surgery: a prospective, randomised study comparing two doses of parnaparin (BAFLUX study).
    Imberti D; Legnani C; Baldini E; Cini M; Nicolini A; Guerra M; De Paoli M; Zanardi A; Palareti G
    Thromb Res; 2009 Dec; 124(6):667-71. PubMed ID: 19482341
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Detection of protamine and heparin after termination of cardiopulmonary bypass by thrombelastometry (ROTEM): results of a pilot study.
    Mittermayr M; Velik-Salchner C; Stalzer B; Margreiter J; Klingler A; Streif W; Fries D; Innerhofer P
    Anesth Analg; 2009 Mar; 108(3):743-50. PubMed ID: 19224778
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Low molecular weight heparins prevent thrombin-induced thrombo-embolism in mice despite low anti-thrombin activity. Evidence that the inhibition of feed-back activation of thrombin generation confers safety advantages over direct thrombin inhibition.
    Momi S; Nasimi M; Colucci M; Nenci GG; Gresele P
    Haematologica; 2001 Mar; 86(3):297-302. PubMed ID: 11255277
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Changing trends in anti-coagulant therapies. Are heparins and oral anti-coagulants challenged?
    Fareed J; Iqbal O; Cunanan J; Demir M; Wahi R; Clarke M; Adiguzel C; Bick R
    Int Angiol; 2008 Jun; 27(3):176-92. PubMed ID: 18506123
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.